14 hours ago
Another Look: Shanghai Henlius Shares Hit A Near Five-Year High
Investigators and global collaborators gathered at the Henlius reception during the annual meeting ... More of the American Society of Clinical Oncology held in Chicago May 30-June 3 this year.
Last Tuesday I posted an interview by Forbes China with Jason Zhu, the CEO of Shanghai Henlius Biotech. Zhu said he sees more growth ahead for the drug maker based on a pipeline of cancer and ophthalmologic drugs, as well as expanded international partnerships.
The company has had a good stretch since. Its Hong Kong-trade shares soared by almost 7% on Thursday from a day earlier to HK$55.95, their highest close in nearly five years. They eased back to HK$55.90 on Friday, but have risen 145% in the past year.
This past week, the company announced EU GMP certification for the production lines of two drug candidates, accelerating their market entry prospects there; it also unveiled a new licensing partnership with HanchorBio. On June 27, Henlius's board approved a package of stock options and restricted stock units for Zhu and other key staff.
Hong Kong-traded shares in Shanghai Fosun Pharmaceutical – which owns more than 60% of Shanghai Henlius – have trended upwards along with the Zhu-led company. They closed at HK$17.08 on Friday, compared with HK$15.92 on June 24.
